Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Dr-Reddy’s"

26 News Found

JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories
News | July 01, 2022

JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories

The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores


Torrent Pharma acquires four brands from Dr Reddy’s
News | May 27, 2022

Torrent Pharma acquires four brands from Dr Reddy’s

The integration and transition of the brands are expected to be completed by June 2022.


Dr Reddy’s appoints Amit Golash as Global Head-Customer Service & Logistics
People | April 22, 2022

Dr Reddy’s appoints Amit Golash as Global Head-Customer Service & Logistics

He has extensive leadership experience across supply chain and has worked at companies such as Unilever, Flipkart, Colgate-Palmolive & Mondelez


Mankind Pharma acquires two brands from Dr Reddy’s
News | February 16, 2022

Mankind Pharma acquires two brands from Dr Reddy’s

The entire integration and transition of the brands is expected to be completed by March 2022


Dr Reddy’s launch generic version of Vasostrict in the US
Drug Approval | February 09, 2022

Dr Reddy’s launch generic version of Vasostrict in the US

The Vasostrict brand market had U.S. sales of approximately US $ 878.5 million MAT for the most recent twelve months ending in December 2021 according to IQVIA Health


Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct
News | January 31, 2022

Dr Reddy’s numbers in line; launches in FY23 likely drivers: ICICI Direct

ICICI Direct analysis of Dr Reddy’s Q3FY22 results


Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021


Dr Reddy’s molnupiravir priced at Rs 1,400 for a course
News | January 04, 2022

Dr Reddy’s molnupiravir priced at Rs 1,400 for a course

Molflu is expected to be available from early next week in pharmacies throughout the country with a particular focus on states with a high caseload of Covid-19.


Dr Reddy’s receives Emergency Use Authorisation for molnupiravir
Drug Approval | December 28, 2021

Dr Reddy’s receives Emergency Use Authorisation for molnupiravir

The company will market it under the brand name Molflu


Dr Reddy’s launch Venlafaxine ER tablets in the US
Drug Approval | December 10, 2021

Dr Reddy’s launch Venlafaxine ER tablets in the US

The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.